search for




 

Case Report
A Case of Ethosuximide-Induced Aplastic Anemia Successfully Treated with Methylprednisolone Pulse Therapy
Clin Pediatr Hematol Oncol 2018;25:175-9.
Published online October 31, 2018
© 2018 Korean Society of Pediatric Hematology-Oncology and Korean Society for Pediatric Neuro-Oncology

Hyun Sik Kang, M.D.1 and Sun Hyung Kim, M.D.2

Departments of 1Pediatrics and 2Laboratory Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea
Correspondence to: Hyun Sik Kang
Department of Pediatrics, Jeju National University School of Medicine, 15 Aran 13-gil, Jeju 63241, Korea
Tel: +82-64-717-1528
Fax: +82-64-717-1097
E-mail: hyunsik.kang@jejunu.ac.kr
ORCID ID: orcid.org/0000-0002-7495-7871
Received September 18, 2018; Revised October 1, 2018; Accepted October 9, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Aplastic anemia may develop secondary to environmental exposure to entities such as chemicals, medical drugs, and infectious agents. Fatal complications from antiepileptic medications may occur despite careful and appropriate use. We report the case of a 9-year-old girl with a presenting diagnosis of aplastic anemia following treatment with ethosuximide for absence seizures. Aplastic anemia can now be cured with stem cell transplantation or immunosuppressive therapy. In this case, however, because of the impossibility of bone marrow transplantation and the specific needs of the patient’s parents, three courses of methylprednisolone pulse therapy were administered. Following the therapy, there was improvement in pancytopenia and complete remission in the bone marrow. No adverse side effects of therapy were observed. The authors suggest that methylprednisolone pulse therapy may be a treatment for acquired aplastic anemia.
Keywords: Aplastic anemia, Ethosuximide, Methylprednisolone, Anticonvulsants
References
  1. Orkin SH, Fisher DE, Ginsburg D, Look AT, Lux SE, Nathan DG. Nathan and Oski's hematology and oncology of infancy and childhood. 8th ed. Philadelphia: Elsevier Saunders, 2015;161-81.
  2. Bacigalupo A. How I treat acquired aplastic anemia. Blood 2017;129:1428-36.
    Pubmed CrossRef
  3. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108:2509-19.
    Pubmed KoreaMed CrossRef
  4. Ibáñez L, Vidal X, Ballarín E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med 2005;165:869-74.
    CrossRef
  5. Handoko KB, Souverein PC, van Staa TP, et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 2006;47:1232-6.
    Pubmed CrossRef
  6. Pulsipher MA, Young NS, Tolar J, et al. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant 2011;17:291-9.
    Pubmed KoreaMed CrossRef
  7. Massey GV, Dunn NL, Heckel JL, Myer EC, Russell EC. Aplastic anemia following therapy for absence seizures with ethosuximide. Pediatr Neurol 1994;11:59-61.
    CrossRef
  8. Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010;362:790-9.
    Pubmed KoreaMed CrossRef
  9. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007;92:11-8.
    Pubmed CrossRef
  10. Schrezenmeier H, Passweg JR, Marsh JCW, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007;110:1397-400.
    Pubmed KoreaMed CrossRef
  11. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995;85:3183-90.
    Pubmed
  12. Tuncer AM, Hiçsönmez G, Gümrük F, et al. Serum TNF-alpha, gamma-INF, G-CSF and GM-CSF levels in neutropenic children with acute leukemia treated with short-course, high-dose methylprednisolone. Leuk Res 1996;20:265-9.
    CrossRef
  13. Shin SH, Lee JW. The optimal immunosuppressive therapy for aplastic anemia. Int J Hematol 2013;97:564-72.
    Pubmed CrossRef
  14. Iwai A, Iwai T, Furukawa S, Hamada Y, Jofuku N. Ethosuximide-induced aplastic anemia successfully treated with bolus methylprednisolone. IRYO 1991;45:676-80.
  15. Tohda S, Suzuki T, Nagata K, Nara N, Aoki N. Successful treatment of a patient with posthepatitic severe aplastic anemia with bolus methylprednisolone. Jpn J Med 1990;29:191-4.
    Pubmed CrossRef


October 2018, 25 (2)
Full Text PDF
Citation
Send to a friend
Twitter
Facebook

Cited By Articles
  • CrossRef (0)

Author ORCID Information
  • Hyun Sik Kang